US pharma major Eli Lilly (NYSE: LLY) has reported positive topline data from its Phase III ATTAIN-MAINTAIN trial, showing that its oral GLP-1 candidate orforglipron helped patients maintain weight ...

Eli Lilly's oral pill helped maintain weight loss in patients switching from its GLP-1 injection, Zepbound, and rival Novo ...

Eli Lilly announced this morning that its investigational obesity pill largely helped patients maintain their weight loss ...

In topline results of the ATTAIN-MAINTAIN trial, people who lost weight with an injectable GLP-1 were able to keep weight off when switched to an oral GLP-1, Eli Lilly announced.For ATTAIN-MAINTAIN, ...

Participants in a Phase III trial who switched to Eli Lilly’s orforglipron after 72 weeks of treatment with Wegovy or ...

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

In the ATTAIN-MAINTAIN study of its orforglipron candidate, switching to the drug after 72 months of injectable treatment ...

Pop Mart, the Chinese firm behind the mischievously grinning, nine-toothed Labubu dolls that shoppers have queued up to buy ...

Popular new anti-obesity medications can help people lose 10% to 20% of their body weight, yet a new study indicates that about 40% of those prescriptions go unfilled. Affordability, say researchers, ...

Even when Americans have health insurance, they can have a hard time affording the drugs they've been prescribed. About 1 in 5 U.S. adults skip filling a prescription due to its cost at least once a ...

Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug ...

Eli Lilly's obesity pill helped patients maintain weight loss after they switched from injectable drugs, outcomes that could ...